The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME). In recent years, it has been well recognized that cancer cells co-exist and co-evolve with their TME, which is often involved in drug resistance. The mTOR pathway modulates the interactions between the stroma and the tumor, thereby affecting both the tumor immunity and angiogenesis. The activation of mTOR signaling is associated with these pro-oncogenic cellular processes, making mTOR a promising target for new combination therapies. This review highlights the role of mTOR signaling in the characterization and the activity of the TME’s elements and their implications in cancer immunotherapy.
Role of mTOR signaling in tumor microenvironment. An overview / Conciatori, Fabiana; Bazzichetto, Chiara; Pilotto, Sara; Bria, Emilio; COGNETTI, FRANCESCO; Falcone, I.; Cognetti, F.; Milella, M.; Ciuffreda, L.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 19:8(2018), pp. 137-143. [10.3390/ijms19082453]
Role of mTOR signaling in tumor microenvironment. An overview
Conciatori, Fabiana;Bazzichetto, Chiara;COGNETTI, FRANCESCO;Falcone I.;Cognetti F.;Milella M.;Ciuffreda L.
2018
Abstract
The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME). In recent years, it has been well recognized that cancer cells co-exist and co-evolve with their TME, which is often involved in drug resistance. The mTOR pathway modulates the interactions between the stroma and the tumor, thereby affecting both the tumor immunity and angiogenesis. The activation of mTOR signaling is associated with these pro-oncogenic cellular processes, making mTOR a promising target for new combination therapies. This review highlights the role of mTOR signaling in the characterization and the activity of the TME’s elements and their implications in cancer immunotherapy.File | Dimensione | Formato | |
---|---|---|---|
Conciatori_Role-of-mTOR_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF | |
Conciatori_T-DM1 and brain metastases Clinical outcome in HER2-positivemetastatic breast cancer.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
568.84 kB
Formato
Adobe PDF
|
568.84 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.